Sorenson John Bradley, EVP of Global Operations, has demonstrated a clear selling bias in his trading activity involving Boston Scientific Corporation (BSX), the only company in which he has reported transactions. Across 42 filings, his total sales amount to $6.5 million, dwarfing his $570,236 in total purchases. The recent activity shows an acceleration of disposals, with eight sales recorded between January and February 2025, including a $671,249 transaction on February 12 and a $685,244 sale on February 7. Smaller but consistent sales occurred throughout February, such as $127,678 on February 14 and $277,417 on February 18, followed by a $347,443 transaction on February 19. Earlier disposals include a $1.26 million sale on May 1, 2024, and two January 2025 transactions totaling $581,241.
While Bradley’s filings include some acquisition activity—notably a $189,984 purchase on January 1, 2025, and a $138,082 transaction in May 2024—these are outweighed by the volume and frequency of sales. The pattern suggests a strategic reduction in his BSX holdings, particularly concentrated in early 2025. The absence of recent buys and the repeated sales at varying dollar amounts indicate a sustained divestment trend rather than isolated rebalancing. All transactions fall under standard SEC reporting codes, with no atypical trading behavior noted in the filings.
AI-assisted summary